A recent study identifies neurological adverse events linked to immune checkpoint inhibitors using disproportionality analysis of the FDA Adverse Event Reporting System. This research highlights the need for increased awareness and monitoring of these potential side effects in patients undergoing treatment.
neurological adverse events associated with immune checkpoint inhibitors identified through disproportionality analysis of the fda adverse event reporting system
Original title: “Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System.”